Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis 2023;82:901-910. doi:10.1136/ard-2022-223715
In figure 1C of the originally published version of the manuscript, the plotted value for All cause death for the Age ≥65 years and Ever smoked group showed the incidence rate (95% Confidence Interval [CI]) (1.81 (1.15, 2.71)) instead of the hazard ratio (HR) vs tumour necrosis factor inhibitors (TNFi (95% CI)) (2.09 (0.85, 5.13)).
This data point has now been corrected to show the HR vs TNFi (95% CI). The corrected figure panel is included below.
